Description
Merimepodib (VX-497) is a novel noncompetitive inhibitor of inosine monophosphate dehydrogenase (IMPDH). Merimepodib is orally bioavailable and inhibits the proliferation of primary human, mouse, rat, and dog lymphocytes at concentrations of approximately 100 nM. It displays broad spectrum antiviral activities.
Merimepodib (VX-497) is a novel noncompetitive inhibitor of inosine monophosphate dehydrogenase (IMPDH). Merimepodib is orally bioavailable and inhibits the proliferation of primary human, mouse, rat, and dog lymphocytes at concentrations of approximately 100 nM. It displays broad spectrum antiviral activities.
Alternate Name/Synonyms: (3S)-oxolan-3-yl N-{[3-({[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]carbamoyl}amino)phenyl]methyl}carbamate,VX-497,VX497
Appearance: Crystalline solid
Formulation:
CAS Number: 198821-22-6
Structure Available?: Yes
Peptide sequence: N/A
Salt Form: No
Molecular Formula: C₂₃H₂₄N₄O₆
Molecular Weight: 452.46
Cell-Permeable?: TRUE
Purity: ≥98%
Solubilities: ~30 mg/ml DMSO
Handling: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.
Country of Origin: USA
Tag Line: A novel noncompetitive IMPDH inhibitor
MDL Number:
PubChem CID: 153241
SMILES: O=C(O[C@@H]1COCC1)NCC2=CC=CC(NC(NC3=CC=C(C4=CN=CO4)C(OC)=C3)=O)=C2
InChi: InChI=1S/C23H24N4O6/c1-30-20-10-17(5-6-19(20)21-12-24-14-32-21)27-22(28)26-16-4-2-3-15(9-16)11-25-23(29)33-18-7-8-31-13-18/h2-6,9-10,12,14,18H,7-8,11,13H2,1H3,(H,25,29)(H2,26,27,28)/t18-/m0/s1
InChi Key: JBPUGFODGPKTDW-SFHVURJKSA-N
Additional Information
Storage Condition: |
-20ºC |
Shipping Condition: |
Gel Pack |
Shelf Life: |
36 months |